Patents by Inventor Reijo Backstrom
Reijo Backstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8318785Abstract: Compounds of formula (I) exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.Type: GrantFiled: July 17, 2006Date of Patent: November 27, 2012Assignee: Orion CorporationInventors: Marko Ahlmark, Reijo Bäckström, Anne Luiro, Jarmo Pystynen, Eija Tiainen
-
Publication number: 20110086852Abstract: Compounds of formula (I), wherein R1-R4, X, Y and Z are as defined in claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.Type: ApplicationFiled: July 17, 2006Publication date: April 14, 2011Applicant: Orion CorporationInventors: Marko AHLMARK, Reijo BACKSTROM, Anne LUIRO, Jarmo PYSTYNEN, Eija TIAINEN
-
Publication number: 20090209532Abstract: Compounds of formula (I) exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.Type: ApplicationFiled: July 17, 2006Publication date: August 20, 2009Inventors: Marko Ahlmark, Reijo Backstrom, Anne Luiro, Jarmo Pystynen, Eija Tiainen
-
Patent number: 6943164Abstract: Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.Type: GrantFiled: November 10, 2003Date of Patent: September 13, 2005Assignee: Orion CorporationInventors: Reijo Bäckström, Päivi Granvik, Ritva Haikala, Sirpa Pelttari, Eva Saukko, Reija Yrjölä
-
Patent number: 6903114Abstract: Compounds of formula (I?), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.Type: GrantFiled: September 14, 2001Date of Patent: June 7, 2005Assignee: Orion CorporationInventors: Reijo Bäckström, Jarmo Pystynen, Timo Lotta, Martti Ovaska, Jyrki Taskinen
-
Publication number: 20040106617Abstract: Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.Type: ApplicationFiled: November 10, 2003Publication date: June 3, 2004Applicant: Orion CorporationInventors: Reijo Backstrom, Paivi Granvik, Ritva Haikala, Sirpa Pelttari, Eva Saukko, Reija Yrjola
-
Patent number: 6730673Abstract: Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.Type: GrantFiled: July 26, 2002Date of Patent: May 4, 2004Assignee: Orion CorporationInventors: Reijo Bäckström, Päivi Granvik, Ritva Haikala, Sirpa Pelttari, Eva Saukko, Reija Yrjölä
-
Patent number: 6699868Abstract: Therapeutically active compounds of formula (I): in which R1 to R4 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, carboxyalkyl, hydroxyalkyl or halogenalkyl, or R2 and R3 form a ring of 5-7 carbon atoms, R5 to R9 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, acyl, hydroxy, alkoxy, alkoxycarbonyl, amino, acylamino, alkylamino, aryloxy, halogen, cyano, nitro, carboxy, alkylsufonyl, sulfonamido or trifluoromethyl, wherein each aryl residue defined above by itself or as a part of another group may be substituted, and pharmaceutically acceptable salts and esters thereof. The compounds increase the calcium sensitivity of contractile proteins of the cardiac muscle and are thus useful in the treatment of congestive heart failure.Type: GrantFiled: December 26, 2002Date of Patent: March 2, 2004Assignee: Orion CorporationInventors: Jarmo Pystynen, Aino Pippuri, Anne Luiro, Pentti Nore, Reijo Bäckström, Kari Lönnberg, Heimo Haikala, Jouko Levijoki, Petri Kaheinen, Juha Kaivola
-
Publication number: 20030158200Abstract: Therapeutically active compounds of formula (I) in which R1 to R4 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, carboxyalkyl, hydroxyalkyl or halogenalkyl, or R2 and R3 form a ring of 5-7 carbon atoms. R5 to R9 means hydrogen, alkyl, alkenyl, aryl, arylalkyl, acyl, hydroxy, alkoxy, alkoxycarbonyl, amino, acylamino, alkylamino, aryloxy, halogen, cyano, nitro, carboxy, alkylsulfonyl, sulfonamido or trifluoromethyl, wherein each aryl residue defined above by itself or as a part of another group may be substituted, and pharmaceutically acceptable salts and esters thereof. The compounds increase the calcium sensitivity of contractile proteins of the cardiac muscle and are thus useful in the treatment of congestive heart failure.Type: ApplicationFiled: December 26, 2002Publication date: August 21, 2003Inventors: Jarmo Pystynen, Aino Pippuri, Anne Luiro, Pentii Nore, Reijo Backstrom, Kari Lonnberg, Heimo Haikala, Jouko Levijoki, Petri Kaheinen, Juha Kaivola
-
Patent number: 6340764Abstract: A pyridazinyl derivative (I) and its use as a reference compound in the determination of potentially genotoxic impurities in levosimendan samples. An analytic method for the determination of potentially genotoxic impurities in levosimendan samples wherein (I) is used as a reference compound. Levosimendan is a medicament useful in the treatment of heart failure.Type: GrantFiled: February 20, 2001Date of Patent: January 22, 2002Assignee: Orion CorporationInventors: Reijo Bäckström, Tuula Heinonen, Tuula Hauta-Aho
-
Patent number: 6201027Abstract: The invention relates to the compounds of formula I: wherein one of X1 and X2 is MeSO2 and the other one is hydrogen or halogen and X3 is hydrogen or halogen. These compounds have been found to be useful in the prevention and the treatment of respiratory diseases, especially asthma, ARDS (Acute Respiratory Distress Syndrome), COPD (chronic obstructive pulmonary diseases), allergic rhinitis and related inflammatory conditions. More specifically, the invention relates to the use of said compound in the prevention and the treatment of asthma in steroid-resistant patients. The invention also relates to pharmaceutical formulations used in the treatment of said diseases.Type: GrantFiled: July 1, 1999Date of Patent: March 13, 2001Assignee: Orion CorporationInventors: Päivi Aho, Reijo Bäckström, Anita Koponen, Inge-Britt Linden, Timo Lotta, Kari Lönnberg, Aino Pippuri, Pentti Pohto
-
Patent number: 6121303Abstract: A compound of formula I ##STR1## wherein R.sub.1 is nitro, halogeno or cyano group and R.sub.2 is a group selected from ##STR2## wherein Y and Z are independently oxygen, sulfur or NR, wherein R is hydrogen, straight or branched C.sub.1-8 alkyl, C.sub.5-7 cycloalkyl, phenylC.sub.1-8 alkyl or phenyl group and X.sub.1 and X.sub.2 are NR, where R is hydrogen, straight or branched C.sub.1-8 alkyl, C.sub.5-7 cycloalkyl, phenylC.sub.1-8 alkyl or phenyl group, or a pharmaceutically acceptable salt or ester thereof. Pharmaceutical compositions are also disclosed.Type: GrantFiled: February 23, 1999Date of Patent: September 19, 2000Assignee: Orion-yhtyma OyInventors: Reijo Backstrom, Erkki Honkanen, Inge-Britt Linden, Erkki Nissinen, Aino Pippuri, Pentti Pohto, Tapio Korkolainen
-
Patent number: 5889037Type: GrantFiled: June 7, 1995Date of Patent: March 30, 1999Assignee: Orion-yhtyma OyInventors: Reijo Backstrom, Erkki Honkanen, Inge-Britt Linden, Erkki Nissinen, Aino Pippuri, Pentti Pohto, Tapio Korkolainen
-
Patent number: 5512571Abstract: Diastereomeric intermediate salts of formulae (IIIa) or (IIIb) ##STR1## are prepared.Type: GrantFiled: May 31, 1995Date of Patent: April 30, 1996Assignee: Orion-yhtyma OyInventors: Pentti Nore, Erkki Honkanen, Reijo Backstrom, Tom Wikberg, Heimo Haikala, Jorma Haarala
-
Patent number: 5424428Abstract: Optically substantially pure (-) enantiomer of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono)prop anedinitrile or pharmaceutically acceptable salt thereof, intermediates and a process for the preparation are described. The product is useful as a cardiotonic agent, antihypertensive and vasodilator for the treatment of congestive heart failure.Type: GrantFiled: June 30, 1993Date of Patent: June 13, 1995Assignee: Orion-yhtyma OyInventors: Pentti Nore, Erkki Honkanen, Reijo Backstrom, Tom Wikberg, Heimo Haikala, Jorma Haarala
-
Patent number: 5362733Abstract: Compounds of formula(I) ##STR1## wherein R.sub.1 is nitro, halo, cyano and R.sub.2 is a group selected from ##STR2## wherein Y is oxygen or sulfur; X.sub.1 is NR wherein R is hydrogen, C.sub.1-8 alkyl or phenyl and pharmaceutically acceptable salts thereof are useful in the prevention or treatment of tissue damage induced by lipid peroxidation.Type: GrantFiled: October 23, 1992Date of Patent: November 8, 1994Assignee: Orion-yhtyma OyInventors: Reijo Backstrom, Erkki Honkanen, Inge-Britt Linden, Erkki Nissinen, Aino Pippuri, Pentti Pohto, Tapio Korkolainen
-
Patent number: 5356923Type: GrantFiled: October 22, 1992Date of Patent: October 18, 1994Assignee: Orion-yhtyma OyInventors: Reijo Backstrom, Erkki Honkanen, Atso Raasmaja, Inge-Birtt Linden
-
Patent number: 5112861Abstract: The invention concerns a method for the treatment of Parkinson's Disease. The method comprises administering a catechol-O-methyl-transferase inhibiting amount of a compound having the formula I ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, alkylcarbamoyl of 2 to 5 carbon atoms or alkylcarbonyl of 2 to 5 carbon atoms, X represents nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents cyano; alkylcarbonyl of 2 to 5 carbon atoms; or carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, or hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable salts or esters thereof; and a sufficient amount of levodopa to treat Parkinson's Disease. A peripheral decarboxylase inhibitor such as carbidopa or benzerazide is also preferably administered.Type: GrantFiled: September 25, 1990Date of Patent: May 12, 1992Assignee: Orion-yhtyma OyInventors: Reijo Backstrom, Kalevi E. Heinola, Erkki J. Honkanen, Seppo K. Kaakkola, Pekka J. Kairisalo, Inge-Britt Y. Linden, Pekka I. Mannisto, Erkki A. O. Nissinen, Pentti Pohto, Aino K. Pippuri, Jarmo Pystynen